Immunogenicity results of different vaccination schemes at different time points. by Rima Moghnieh (679199)

Subjects:

Effectiveness of the available COVID-19 primary and booster vaccination schemes against laboratory-confirmed infections during the different waves. by Rima Moghnieh (679199)

Subjects:

Effectiveness of the available COVID-19 primary and booster vaccination schemes against acute-care hospitalization attributed to laboratory-confirmed infections during the differen... by Rima Moghnieh (679199)

Subjects:

Immunogenicity assessment groups based on the primary and booster vaccination schemes and timeframe from the second or booster dose. by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Omicron BA.4/BA.5 variant wave. by Rima Moghnieh (679199)

Subjects:

Humoral immune responses to SARS-CoV-2 spike protein following various primary vaccination schemes and booster doses with Sinopharm or Pfizer vaccines among COVID-19-naïve particip... by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Alpha variant wave. by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Omicron BA.1/BA.2 variant wave. by Rima Moghnieh (679199)

Subjects:

Fig 4 - by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Delta variant wave. by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the mixed Delta and Omicron variant wave. by Rima Moghnieh (679199)

Subjects:

COVID-19 in Lebanon: The daily number of COVID-19 cases throughout the waves of the pandemic in Lebanon and associated SARS-CoV-2 variants between January 2021 and September 2022. by Rima Moghnieh (679199)

Subjects:

Study profile. by Rima Moghnieh (679199)

Subjects:

Fig 3 - by Rima Moghnieh (679199)

Subjects:

ELISA analysis revealed a significant decrease in SP (A & B) and CGRP (C & D) protein levels in the corneas and tear fluid of mice treated with 0.5% bupivacaine (BUP) every alternate day for 15 days (administered via subconjunctival injection (SCI) alone or in combination with topical (TOP) application) compared to PBS-treated controls. by Ananya Datta (19932144)

The (A) logistic regression model (LRM) and (B) random forest model (RFM) with only conservation scores as independent variables (orange, yellow) show decreased model fitting metri... by Bushra Haque (20513785)

EF-24 treatment significantly reduces cell viability in leukemia cell lines. by Ajeet P. Singh (22298432)

Subjects:

Histological scoring system of burned dermis. by Omid Mehrpour (9385929)

Subjects:

Histological scoring system of burned epidermis. by Omid Mehrpour (9385929)

Subjects:

Results of redundancy analysis. by Bianhua Zhang (22430652)

Subjects: “…aggregation coefficient decreased…”